Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by jopatcloon Jan 22, 2024 8:36am
149 Views
Post# 35838593

"Dear Friend; Bravo Dr. George Adams ICD.D"

"Dear Friend; Bravo Dr. George Adams ICD.D"
"Dear Friend;
 
Attached is today’s press release and a link to a recent news story about the Company.
 
Here is some background:
 
1. Dr. Mertens was the person I first consulted when the Ventripoint opportunity was presented to me in 2010 as he was then and still is one of the top paediatric cardiologists.  He coined the term “the lost ventricle” for the right ventricle of the heart.
2. He continues to head the echocardiography unit at the Hospital for Sick Children, which is also famous worldwide for innovative clinical care.
3. According to research gate he has 559 publications, which have been cited by other publications 16,287 times.  That is a lot! - and shows just how much of an influencer he is.
4. He was the first one to publish the comparison between MRI and VMS+ in children with CHD (Tetrology of Fallot).
5. He ran the core reference lab for the Company’s pivotal study on Pulmonary Hypertension, which resulted in the first FDA clearance.
6. He has always been supportive, but in a quiet way, so it is with great joy, we announce today that he has joined the Clinical Advisory Board.
7. The association of key opinion leaders with the Company is important to the ongoing effort to drive adoption of its breakthrough VMS+ products.
8. Here also is a link to the new story about the Company which came out late last week.  Health-AI, It’s Not Just for Drug Discovery. Ventripoint Diagnostics… (canadahealthwatch.ca)
 
Thank you for your continued support and interest as we march on to change cardiac diagnostics and care for everyone, everywhere, and especially for children born with a heart defect.
 
Regards,
 
Dr. George Adams ICD.D"
<< Previous
Bullboard Posts
Next >>